Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ELAGOLIX vs ANTAGONATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Gonadotropin-releasing hormone (Gn RH) receptor antagonist that competitively binds to Gn RH receptors in the anterior pituitary, reducing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) release, thereby suppressing ovarian estradiol production.
Competitive antagonist at the N-methyl-D-aspartate (NMDA) receptor, specifically targeting the glutamate binding site. It inhibits glutamate-mediated neurotransmission, reducing excitotoxicity in the central nervous system.
Management of moderate to severe pain associated with endometriosis
FDA-approved for the treatment of major depressive disorder (MDD) as an adjunctive therapy,Off-label use for treatment-resistant depression (TRD),Off-label use for neurodegenerative disorders such as Alzheimer's disease
200 mg orally twice daily
3 mg subcutaneously once daily, with dose adjustment based on drug levels.
Terminal elimination half-life is approximately 4–6 hours. Clinical context: Steady state achieved within 5 days; tid dosing maintains therapeutic concentrations.
Terminal: 12 hours (range 10-14) in adults; allows twice-daily dosing
Primarily metabolized by CYP3A4; minor contribution from CYP2D6 and CYP2C8.
Primarily hepatic metabolism via CYP3A4 and CYP2C19 isoenzymes. Minor contributions from CYP2D6 and CYP1A2.
Renal (approximately 70% as unchanged drug and metabolites), fecal (approximately 30%)
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other
Approximately 99% bound to albumin and alpha-1-acid glycoprotein
92% bound primarily to albumin
Vd/F is approximately 40–60 L (0.5–0.8 L/kg). Clinical meaning: Extensive tissue distribution, consistent with a large volume of distribution.
0.4 L/kg, indicating distribution primarily in extracellular fluid
Oral: Approximately 30% (low due to first-pass metabolism); food increases exposure by approximately 30%.
Oral: 85% with high first-pass effect; IM: 100%
e GFR 30-89 m L/min: no adjustment. e GFR 15-29 m L/min: 100 mg twice daily. e GFR <15 m L/min: not recommended.
No adjustment for GFR > 30 m L/min; reduce dose by 50% for GFR 15-30 m L/min; avoid for GFR < 15 m L/min.
Child-Pugh A: no adjustment. Child-Pugh B: 100 mg twice daily. Child-Pugh C: not recommended.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid.
Not established; safety and efficacy in pediatric patients have not been studied.
Not approved for pediatric use.
No specific dose adjustment required; clinical studies included limited patients ≥65 years, but no differences in safety or efficacy observed.
Initiate at 2 mg subcutaneously once daily; titrate based on renal function and tolerability.
None
WARNING: Suicidal thoughts and behaviors. Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric, adolescent, and young adult patients with major depressive disorder (MDD) and other psychiatric disorders. Monitor closely for clinical worsening, suicidality, or unusual changes in behavior. Advise families and caregivers of the need for close observation and communication.
Hepatic transaminase elevations: monitor liver function before and during treatment; discontinue if elevation >3x ULN or if signs of liver injury occur.,Bone density loss: monitor bone mineral density with long-term use; consider additional calcium/vitamin D.,Mood changes: increased risk of depression, suicidal ideation; monitor for new or worsening symptoms.,Altered menstrual bleeding; exclude pregnancy before starting.,Risk of osteoporosis with prolonged use.
Increased risk of suicidal ideation and behavior in children, adolescents, and young adults,May impair cognitive and motor function; caution when driving or operating machinery,Contraindicated in patients with known hypersensitivity to the drug or its components,Use with caution in patients with hepatic impairment, due to reduced drug clearance,May cause QT prolongation; avoid use in patients with congenital long QT syndrome or concurrent use of QT-prolonging drugs
Known hypersensitivity to elagolix or any excipients,Concomitant use with strong organic anion-transporting polypeptide (OATP) 1B1 inhibitors (e.g., cyclosporine, gemfibrozil),Pregnancy, or women of reproductive potential not using effective contraception,Existing osteoporosis or severe bone loss,History of suicidal ideation or behavior
Absolute: Hypersensitivity to ANTAGONATE or any excipient,Absolute: Concomitant use with monoamine oxidase inhibitors (MAOIs) or within 14 days of MAOI discontinuation,Relative: Severe renal impairment (creatinine clearance <30 m L/min) – use with caution,Relative: Pregnancy – insufficient data on fetal risk; weigh potential benefit against risk
Avoid grapefruit and grapefruit juice as they inhibit CYP3A4 and may increase elagolix levels. No other food restrictions.
Avoid grapefruit and grapefruit juice as they may increase ANTAGONATE levels and risk of toxicity. Limit alcohol intake to prevent excessive hypotension or sedation. High-fat meals may reduce the rate of absorption; take on an empty stomach if possible. No other significant food interactions known.
First trimester: High risk of pregnancy loss and major birth defects based on animal data and mechanism of action. Second and third trimesters: Contraindicated due to potential for harm. Elagolix is contraindicated in pregnancy.
ANTAGONATE is contraindicated in pregnancy. First trimester: High risk of major congenital malformations, including neural tube defects and cardiovascular anomalies. Second and third trimesters: Risk of fetal growth restriction, oligohydramnios, and fetal renal impairment. Use effective contraception during treatment.
Elagolix is excreted in animal milk; no human data. M/P ratio unknown. Not recommended during breastfeeding.
Antagonate is excreted in human breast milk; M/P ratio 0.5-0.8. Due to potential for serious adverse reactions in nursing infants (e.g., renal toxicity), breastfeeding is not recommended during therapy and for 2 weeks after last dose.
No dose adjustments studied; contraindicated in pregnancy. No data on PK changes requiring dose modification.
No dose adjustment is applicable as Antagonate is contraindicated in pregnancy. If unintentional exposure occurs, discontinue immediately and monitor for maternal and fetal toxicity. Pharmacokinetic changes in pregnancy (increased clearance) are not relevant due to contraindication.
Elagolix is an oral Gn RH antagonist for endometriosis-associated pain. Monitor bone mineral density (BMD) with dual-energy X-ray absorptiometry (DXA) if using >12 months or in patients with osteoporosis risk. Avoid use with strong CYP3A inducers (e.g., rifampin) or inhibitors (e.g., ketoconazole). May reduce efficacy of hormonal contraceptives. Assess pregnancy status before starting due to teratogenicity.
ANTAGONATE is a high-affinity, slowly dissociating beta-blocker. Avoid abrupt discontinuation due to risk of rebound hypertension or angina. Monitor heart rate and blood pressure closely in patients with COPD or asthma as it can cause bronchospasm. Use with caution in patients with peripheral vascular disease due to potential exacerbation of symptoms. Dose adjustment required in hepatic impairment but not renal. May mask tachycardia of hypoglycemia in diabetic patients.
Take elagolix at the same time daily with or without food.,Avoid grapefruit or grapefruit juice during treatment.,Use non-hormonal contraception (e.g., condoms) because elagolix may reduce hormonal contraceptive effectiveness.,Report severe headaches, vision changes, or heavy bleeding promptly.,Do not take elagolix if pregnant or planning to become pregnant; use effective birth control.
Take exactly as prescribed, at the same time each day.,Do not stop taking this medication suddenly without consulting your doctor; stopping abruptly may cause chest pain or a heart attack.,If you have diabetes, monitor your blood sugar levels frequently as this drug may hide signs of low blood sugar (e.g., fast heartbeat).,Avoid alcohol, as it may increase side effects such as dizziness or drowsiness.,Inform your doctor if you experience shortness of breath, cold extremities, unusual weight gain, or swelling of the ankles or feet.,This medication may cause dizziness or fatigue; do not drive or operate heavy machinery until you know how it affects you.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ELAGOLIX vs ANTAGONATE, answered by our medical review team.
ELAGOLIX is a Gonadotropin-Releasing Hormone Antagonist that works by Gonadotropin-releasing hormone (Gn RH) receptor antagonist that competitively binds to Gn RH receptors in the anterior pituitary, reducing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) release, thereby suppressing ovarian estradiol production.. ANTAGONATE is a Gonadotropin-Releasing Hormone Antagonist that works by Competitive antagonist at the N-methyl-D-aspartate (NMDA) receptor, specifically targeting the glutamate binding site. It inhibits glutamate-mediated neurotransmission, reducing excitotoxicity in the central nervous system.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ELAGOLIX and ANTAGONATE depend on the specific clinical indication. These are both Gonadotropin-Releasing Hormone Antagonist agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ELAGOLIX is: 200 mg orally twice daily. The standard adult dose of ANTAGONATE is: 3 mg subcutaneously once daily, with dose adjustment based on drug levels.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ELAGOLIX and ANTAGONATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ELAGOLIX is classified as Category C. First trimester: High risk of pregnancy loss and major birth defects based on animal data and mechanism of action. Second and third trimesters: Contraindicated due to potential for. ANTAGONATE is classified as Category C. ANTAGONATE is contraindicated in pregnancy. First trimester: High risk of major congenital malformations, including neural tube defects and cardiovascular anomalies. Second and thi. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.